Telomir Pharmaceuticals Approves CEO Compensation Adjustments Including Incentive Payouts and Salary Increase

Telomir Pharmaceuticals, Inc.

CEO Erez Aminov received a 2025 short-term incentive payout of $400,000 for operational and financing achievements.
Contingent milestone payout of $150,000 approved for future FDA acceptance of the Telomir-1 IND submission.
Transaction advisory award of 3% of the total TELI acquisition value granted for leadership in negotiating the potential acquisition.
Base salary adjusted to $500,000 effective January 1, 2026, based on external benchmarking.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.